Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $249,582 | $412,900 | $1,017,000 | $11,827,091 |
| - Cash | $36,997 | $135,704 | $81,347 | $186,816 |
| + Debt | $8,375 | $11,138 | $12,574 | $14,455 |
| Enterprise Value | $220,960 | $288,334 | $948,227 | $11,654,730 |
| Revenue | $3,945 | $15,529 | $13,907 | $4,359 |
| % Growth | -74.6% | 11.7% | 219% | – |
| Gross Profit | $3,945 | $15,529 | $13,907 | $4,359 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$86,532 | -$85,058 | -$93,905 | -$124,543 |
| % Margin | -2,193.5% | -547.7% | -675.2% | -2,857.1% |
| Net Income | -$131,211 | -$87,679 | -$96,046 | -$128,332 |
| % Margin | -3,326% | -564.6% | -690.6% | -2,944.1% |
| EPS Diluted | -20.94 | -3.52 | -2.25 | -3.22 |
| % Growth | -494.9% | -56.4% | 30.1% | – |
| Operating Cash Flow | -$80,743 | -$78,997 | -$79,389 | -$115,662 |
| Capital Expenditures | -$130 | -$19 | -$943 | -$892 |
| Free Cash Flow | -$80,873 | -$79,016 | -$80,332 | -$116,554 |